TS23

BIOLOGICAL3 trials

Sponsors

Translational Sciences, Inc.

Conditions

Cerebral IschemiaIschemic StrokeMyocardial InfarctionPulmonary EmbolismThrombosisVenous Thrombosis

Phase 1

Study of Safety and Biomarker Efficacy of TS23 in Healthy Volunteer

Translational Sciences, Inc.Cerebral Ischemia, Myocardial Infarction, Pulmonary Embolism +2

Start: 2015-07-31End: 2017-06-30Updated: 2016-12-23

Phase 2

Novel α2-Antiplasmin Inactivation for Lysis of Intravascular Thrombi (NAIL-IT) Trial

Active, not recruitingNCT05408546

Translational Sciences, Inc.Pulmonary Embolism

Start: 2023-05-24End: 2026-11-01Target: 64Updated: 2026-07-01

Strategy for Improving Stroke Treatment Response

RecruitingNCT05948566

Translational Sciences, Inc.Ischemic Stroke

Start: 2024-03-18End: 2027-12-01Target: 300Updated: 2026-08-24

Related Papers

Neurointerventional Practice Change Following Distal Medium Vessel Occlusion Randomized Controlled Trials: A Survey.

2026-01-06